BridgeBio Pharma (BBIO) Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BBIO shares.
View BBIO analyst ratings or view top-rated stocks.

9 brokerages have issued 12 month target prices for BridgeBio Pharma's shares. Their BBIO share price forecasts range from $18.00 to $40.00. On average, they anticipate the company's stock price to reach $26.63 in the next year. This suggests a possible upside of 93.6% from the stock's current price.
View analysts price targets for BBIO or view top-rated stocks among Wall Street analysts.

BridgeBio Pharma's stock was trading at $7.62 at the beginning of 2023. Since then, BBIO shares have increased by 80.4% and is now trading at $13.75.
View the best growth stocks for 2023 here.

BridgeBio Pharma saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 13,290,000 shares, a decrease of 6.4% from the April 30th total of 14,200,000 shares. Based on an average daily trading volume, of 3,140,000 shares, the days-to-cover ratio is presently 4.2 days. Approximately 11.5% of the shares of the stock are sold short.
View BridgeBio Pharma's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our BBIO earnings forecast.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) released its earnings results on Thursday, May, 4th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.09. The firm earned $1.83 million during the quarter, compared to analyst estimates of $3.23 million. The business's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.35) earnings per share.

ETFs with the largest weight of BridgeBio Pharma (NASDAQ:BBIO) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), WisdomTree BioRevolution Fund (WDNA), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).

Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU), Editas Medicine (EDIT), Block (SQ), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT).

(BBIO) raised $225 million in an IPO on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR served as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

BridgeBio Pharma trades on the NASDAQ under the ticker symbol "BBIO."

BridgeBio Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Hhlr Advisors LTD. (2.48%), Geode Capital Management LLC (1.40%), Perceptive Advisors LLC (1.19%), Pictet Asset Management SA (0.90%), Ensign Peak Advisors Inc (0.67%) and Charles Schwab Investment Management Inc. (0.58%). Insiders that own company stock include Brian C Stephenson, Cameron Turtle, Charles J Homcy, Douglas A Dachille, Genetic Disorder LP Kkr, Michael Thomas Henderson, Neil Kumar, Randal W Scott, Richard H Scheller and Ronald J Daniels.
View institutional ownership trends.

Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BBIO stock can currently be purchased for approximately $13.75.

BridgeBio Pharma (NASDAQ:BBIO) has a market capitalization of $2.21 billion and generates $77.65 million in revenue each year. The company earns $-481,180,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis.

The company employs 576 workers across the globe.

BridgeBio Pharma's mailing address is 421 Kipling Street, Palo Alto CA, 94301. The official website for the company is bridgebio.com. The company can be reached via phone at (650) 391-9740.